Topline results from the LUCIA phase 3 trial for DURAVYU failed to meet the primary endpoint for statistical non-inferiority, while demonstrating a successful safety profile and a 38% reduction in injections.
Topline results from the LUCIA phase 3 trial for DURAVYU failed to meet the primary endpoint for statistical non-inferiority, while demonstrating a successful safety profile and a 38% reduction in injections.